News

US-based ZS Pharma develops and commercializes highly selective, non-absorbed drugs for the treatment of renal, cardiovascular, liver and metabolic disorders. The company employs about 200 people across three

The investigational drug SM04690 is a small molecule inhibitor of the Wnt pathway. The approximately 400 patient trial will study three different doses of SM04690 against a placebo,

The study, which appears in the journal ACS Nano, shows how the nanoparticle system targets the precise cells infected by the bacteria and maximizes the amount of drug

This innovative funding approach, into a cancer with low survival rates and in urgent need of better treatments, will support over 24 researchers across the UK and US

Launched in India in 1980, Little’s is present across a wide range of products including – baby feeding bottles, baby skin-care, baby grooming accessories, baby apparels and baby

This action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015, respectively. Dr. Reddy’s CEO G V Prasad said:

Additionally, Agenus obtained an exclusive license to a phage display library from IONTAS, and entered into an agreement for cell line development technology with Selexis. These new capabilities,

MD Anderson will leverage its expertise in developing allogeneic umbilical cord blood and peripheral blood derived NK-cell therapies and combine it with CytomX’s Probody technology to address new

Sotagliflozin (LX4211) is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for diabetes patients.